Skip to main content
. 2024 Jul 18;21(7):e1004429. doi: 10.1371/journal.pmed.1004429

Fig 5. Most cost-effective option* when TCZ is available.

Fig 5

* The “most cost-effective option” is the option most likely to be cost-effective based on simulation of 1,000 parameter sets. PCR, polymerase chain reaction; RDT, rapid diagnostic tests; TCZ, tocilizumab. Dotted lines are used to represent options in which TCZ is used, whereas full lines represent options in which it is not. LICs, low-income countries (27 countries); LMICs, lower-middle-income countries (54 countries); UMICs, upper-middle-income countries (48 countries).